



Organoid Models for Metabolic Diseases and Cancer

Guest Editor:

Dr. Cyril Corbet

Pole of Pharmacology and
Therapeutics (FATH), Institut de
Recherche Expérimentale et
Clinique, UCLouvain, 1200
Brussels, Belgium

Deadline for manuscript
submissions:

closed (31 December 2024)

Message from the Guest Editor

Dear colleagues,

The aim of this Special Issue of *Organoids* is to present new reports that advance the knowledge on the use of organoids in the study of (stem) cell metabolism in several pathophysiological contexts, such as cancer, metabolic diseases, and alterations in diet–microbe–host interactions. We welcome the submission of original research articles and reviews that focus on all aspects of organoid development, disease modeling, drug screening, and technological advancements towards applications in the study of cell metabolism.

Keywords

- organoids
- metabolism
- stem cells
- metabolic diseases
- diabetes
- cancer
- tumor microenvironment
- disease modeling
- personalized medicine





Editor-in-Chief

Prof. Dr. Süleyman Ergün

Institute of Anatomy and Cell
Biology, University of Würzburg,
97070 Würzburg, Germany

Message from the Editor-in-Chief

Functional human 3D tissue models are attractive platforms for disease studies, drug development and toxicity testing. They serve as a bridge between cell cultures, animal models and clinical trials. Such models are called organoids. Numerous scientists worldwide are currently researching the generation of new complex organoid models and improving culturing conditions to handle them in a way that is reproducible, cost-effective, and easy. Achieving this goal is still a major challenge, but the organoid field has developed rapidly in recent years, reaching a new level of complexity and playing a growing role in medical research. Organoids' goal is to create a platform to present new and exciting data covering all aspects of organoid, assembloid, embryoid, or organ-on-a-chip research.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **ESCI (Web of Science)**, **Scopus**, and many **other databases**.

Rapid Publication: manuscripts are peer-reviewed and a first decision is provided to authors approximately 27.8 days after submission; acceptance to publication is undertaken in 3.2 days (median values for papers published in this journal in the second half of 2025).

Contact Us

Organoids Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/organoids
organoids@mdpi.com
[X@Organoids_MDPI](https://twitter.com/Organoids_MDPI)